<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:45:10Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9210861" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9210861</identifier>
        <datestamp>2022-06-30</datestamp>
        <setSpec>diacare</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
              <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
              <journal-id journal-id-type="publisher-id">diabetes care</journal-id>
              <journal-title-group>
                <journal-title>Diabetes Care</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0149-5992</issn>
              <issn pub-type="epub">1935-5548</issn>
              <publisher>
                <publisher-name>American Diabetes Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9210861</article-id>
              <article-id pub-id-type="pmcid">PMC9210861</article-id>
              <article-id pub-id-type="pmc-uid">9210861</article-id>
              <article-id pub-id-type="pmid">35472672</article-id>
              <article-id pub-id-type="pmid">35472672</article-id>
              <article-id pub-id-type="publisher-id">212034</article-id>
              <article-id pub-id-type="doi">10.2337/dc21-2034</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Cardiovascular and Metabolic Risk</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2235-0103</contrib-id>
                  <name>
                    <surname>Tuttle</surname>
                    <given-names>Katherine R.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levin</surname>
                    <given-names>Adeera</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nangaku</surname>
                    <given-names>Masaomi</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kadowaki</surname>
                    <given-names>Takashi</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff"/>
                  <xref rid="aff4" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Agarwal</surname>
                    <given-names>Rajiv</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hauske</surname>
                    <given-names>Sibylle J.</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff"/>
                  <xref rid="aff7" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Elsäßer</surname>
                    <given-names>Amelie</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ritter</surname>
                    <given-names>Ivana</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Steubl</surname>
                    <given-names>Dominik</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff"/>
                  <xref rid="aff8" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wanner</surname>
                    <given-names>Christoph</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wheeler</surname>
                    <given-names>David C.</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Providence Health Care, University of Washington, Spokane, WA</aff>
              <aff id="aff2"><label>2</label>University of British Columbia, Vancouver, British Columbia, Canada</aff>
              <aff id="aff3"><label>3</label>Graduate School of Medicine, The University of Tokyo, Tokyo, Japan</aff>
              <aff id="aff4"><label>4</label>Toranomon Hospital, Tokyo, Japan</aff>
              <aff id="aff5"><label>5</label>Indiana University, Indianapolis, IN</aff>
              <aff id="aff6"><label>6</label>Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim, Germany</aff>
              <aff id="aff7"><label>7</label>Vth Department of Medicine, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany</aff>
              <aff id="aff8"><label>8</label>Department of Nephrology, Faculty of Medicine, Technical University Munich, Munich, Germany</aff>
              <aff id="aff9"><label>9</label>Würzburg University Clinic, Würzburg, Germany</aff>
              <aff id="aff10"><label>10</label>University College London, London, U.K</aff>
              <author-notes>
                <corresp id="cor1">Corresponding author: Katherine R. Tuttle, <email>katherine.tuttle@providence.org</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-04-26">
                <day>26</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>45</volume>
              <issue>6</issue>
              <fpage>1445</fpage>
              <lpage>1452</lpage>
              <history>
                <date date-type="received" iso-8601-date="2021-09-29">
                  <day>29</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted" iso-8601-date="2022-03-25">
                  <day>25</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 by the American Diabetes Association</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref start_date="2022-04-26">https://www.diabetesjournals.org/content/license</ali:license_ref>
                  <license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <ext-link ext-link-type="uri" xlink:href="https://www.diabetesjournals.org/journals/pages/license">https://www.diabetesjournals.org/journals/pages/license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="dc212034.pdf"/>
              <abstract>
                <sec id="s1">
                  <title>OBJECTIVE</title>
                  <p>To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3–4) enrolled in clinical trials.</p>
                </sec>
                <sec id="s2">
                  <title>RESEARCH DESIGN AND METHODS</title>
                  <p>This analysis pooled data from 19 randomized, placebo-controlled, phase 1–4 clinical trials and 1 randomized, placebo-controlled extension study in which patients received empagliflozin 10 mg or 25 mg daily. Time to first occurrence of adverse events (AEs) was evaluated using Kaplan-Meier analysis and multivariable Cox regression models.</p>
                </sec>
                <sec id="s3">
                  <title>RESULTS</title>
                  <p>Among a total of 15,081 patients who received at least one study drug dose, 1,522, 722, and 123 were classified as having G3A, G3B, and G4 CKD, respectively, at baseline. Demographic and clinical characteristics were similar between treatment groups across CKD categories. Rates of serious AEs, AEs leading to discontinuation, and events of special interest (including lower limb amputations and acute renal failure [ARF]) were also similar between empagliflozin and placebo across CKD subgroups. In adjusted Cox regression analyses, risks for volume depletion and ARF were similar for empagliflozin and placebo in the combined group with CKD categories G3B and G4 and the G3A group. Notably lower risks were observed in both groups for hyperkalemia (hazard ratio 0.59 [95% CI 0.37–0.96, <italic toggle="yes">P</italic> = 0.0323] and 0.48 [0.26–0.91, <italic toggle="yes">P</italic> = 0.0243], respectively) and edema (0.47 [0.33–0.68, <italic toggle="yes">P</italic> &lt; 0.0001] and 0.44 [0.28–0.68, <italic toggle="yes">P</italic> = 0.0002], respectively).</p>
                </sec>
                <sec id="s4">
                  <title>CONCLUSIONS</title>
                  <p>Use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s5">
              <title>Introduction</title>
              <p>Type 2 diabetes is the leading cause of chronic kidney disease (CKD) worldwide (<xref rid="B1" ref-type="bibr">1</xref>). CKD, characterized by the presence of albuminuria and/or a decline in glomerular filtration rate, develops in ∼40% of patients with type 2 diabetes (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). During the course of CKD in diabetes, the annual decline in estimated glomerular filtration rate (eGFR) varies greatly depending on the severity of CKD and the presence of risk factors such as hyperglycemia, hypertension, obesity, and smoking (<xref rid="B4" ref-type="bibr">4</xref>). CKD attributed to diabetes is the leading global cause of kidney failure, requiring dialysis treatment or a kidney transplant (<xref rid="B5" ref-type="bibr">5</xref>). Both eGFR &lt;60 mL/min/1.73 m<sup>2</sup> and albuminuria are independent predictors of cardiovascular events and mortality (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>), meaning that patients with diabetes and concomitant CKD are a particularly high-risk population.</p>
              <p>Interventions to prevent or slow CKD progression are essential to reduce risks for serious complications (<xref rid="B8" ref-type="bibr">8</xref>). Empagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been shown to reduce onset and progression of CKD in patients with type 2 diabetes (<xref rid="B8" ref-type="bibr">8</xref>). Current U.S. Food and Drug Administration prescribing information allows for empagliflozin to be used in patients with an eGFR ≥30 mL/min/1.73 m<sup>2</sup> (<xref rid="B9" ref-type="bibr">9</xref>), but labeling may vary from country to country. However, both kidney and cardiovascular benefits have been observed with empagliflozin in patients with heart failure and an eGFR as low as 20 mL/min/1.73 m<sup>2</sup>, irrespective of diabetes status (<xref rid="B10" ref-type="bibr">10</xref>).</p>
              <p>In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), a cardiovascular outcome trial that included patients with type 2 diabetes and established cardiovascular disease with an eGFR ≥30 mL/min/1.73 m<sup>2</sup>, empagliflozin added to the standard of care reduced cardiovascular death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% compared with placebo (<xref rid="B11" ref-type="bibr">11</xref>); there was also a 39% reduction in incident or worsening nephropathy (<xref rid="B12" ref-type="bibr">12</xref>). Notably, the safety profile of empagliflozin in patients with CKD category G3 (eGFR 30 to &lt;60 mL/min/1.73 m<sup>2</sup>) was consistent with that of the overall trial population (<xref rid="B12" ref-type="bibr">12</xref>), and observed rates of adverse events (AEs) of particular concern in this population, such as rates of urinary tract and genital infections, volume depletion, acute renal failure (ARF), hyperkalemia, hypoglycemia, bone fracture, and lower limb amputations, were not different from rates seen in patients receiving placebo (<xref rid="B13" ref-type="bibr">13</xref>).</p>
              <p>A large pooled analysis of data from the empagliflozin clinical trial program has previously reported safety analyses (<xref rid="B14" ref-type="bibr">14</xref>). The present analysis reports safety data for AEs that are particularly relevant in this population with type 2 diabetes and moderate to severe CKD (CKD categories G3–4) who were enrolled in these clinical trials.</p>
            </sec>
            <sec id="s6">
              <title>Research Design and Methods</title>
              <p>The pooled analysis included data from 19 randomized, placebo-controlled, phase 1–4 clinical trials (including EMPA-REG OUTCOME) and 1 extension study that included participants from 3 of the 19 included trials (<ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Table 1</ext-link>). All trials enrolled patients with type 2 diabetes. The data pool comprised placebocontrolled trials in which participants received empagliflozin 10 mg or 25 mg daily, including some that involved dose escalation or uptitration from the 10 to the 25 mg dose. No studies of open-label treatment or active comparators were included.</p>
              <sec id="s7">
                <title>Safety Assessment</title>
                <p>Safety was assessed based on investigator-reported AEs that were coded according to preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA) version 21.0. Serious AEs (SAEs) were defined as any AE that resulted in death, was immediately life threatening, resulted in persistent or marked disability/incapacity, required or prolonged inpatient hospitalization, was a congenital anomaly/birth defect, or was deemed serious for any other reason. Hypoglycemia, including all confirmed hypoglycemic events (with a glucose value ≤70 mg/dL or where assistance was required), and other defined events of special interest were identified by a search of MedDRA preferred terms. As lower limb amputations were not usually captured in AE reports, the frequency of lower limb amputations was assessed based on a medical review of the pooled safety data and AE narratives (<xref rid="B15" ref-type="bibr">15</xref>).</p>
              </sec>
              <sec id="s8">
                <title>Data Analyses</title>
                <p>The eGFR was calculated from the serum creatinine (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation 2009). AEs were assessed in all participants who received at least one study drug dose. Exposure-adjusted incidence rates were calculated per 100 patient-years as 100 × <italic toggle="yes">n</italic>/T, where <italic toggle="yes">n</italic> was the number of participants with the event and T the total patient-years at risk for the event. Patient-years at risk were defined as the time from the first dose of study treatment received to the onset of the first event (for those with an event) or to the last dose plus 7 days (for those without an event). Time to first occurrence of events consistent with edema, hyperkalemia, bone fracture, volume depletion, and ARF was evaluated by Kaplan-Meier analysis (MedDRA terms, <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Table 2</ext-link>). Cox regression analyses were performed for hyperkalemia, edema, volume depletion, and ARF. The Cox regression models for time to first event included the following covariables: age, baseline BMI, baseline HbA<sub>1c</sub>, treatment, sex, baseline eGFR, and a treatment-by-baseline eGFR interaction term. To check for heterogeneity, the Cox regression models were repeated with EMPA-REG OUTCOME versus other trials as a categorical class variable in the model and with the individual study as a random effect, both in addition to the standard parameterization used in the analysis.</p>
              </sec>
              <sec id="s9">
                <title>Data and Resource Availability</title>
                <p>The sponsor of the EMPA-REG OUTCOME trial (Boehringer Ingelheim) is committed to responsible sharing of clinical trial reports, related clinical documents, and patient-level clinical data. Researchers are invited to submit inquiries through the Vivli Center for Global Clinical Research website (<ext-link xlink:href="https://vivli.org" ext-link-type="uri">https://vivli.org</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s10">
              <title>Results</title>
              <sec id="s11">
                <title>Analysis Population</title>
                <p>In total, 15,081 patients were included in the pooled analysis population. Baseline eGFR was &lt;60 mL/min/1.73 m<sup>2</sup> in 2,367 patients (1,519 who received empagliflozin 10 or 25 mg; 848 who received placebo). A total of 1,522, 722, and 123 patients were classified as having CKD categories G3A (eGFR 45 to &lt;60 mL/min/1.73 m<sup>2</sup>), G3B (eGFR 30 to &lt;45 mL/min/1.73 m<sup>2</sup>), and G4 (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>), respectively. Total exposure for the placebo and empagliflozin groups, respectively, was 1,014 and 2,021 patient-years in CKD category G3A, 503 and 850 patient-years in CKD category G3B, and 50 and 89 patient-years in CKD category G4. The proportion of patients with normoalbuminuria, microalbuminuria, or macroalbuminuria was similar across the empagliflozin (66.3%, 24.8%, and 7.7%, respectively) and placebo (64.5%, 25.6%, and 8.9%, respectively) treatment groups. Demographic and baseline characteristics were similar between patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> in the empagliflozin and placebo groups across these CKD categories (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Demographic and baseline characteristics of the pooled analysis population with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> (<italic toggle="yes">N</italic> = 2,367)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="6" rowspan="1">CKD category and study treatment</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="2" rowspan="1">G3A</th>
                        <th align="center" colspan="2" rowspan="1">G3B</th>
                        <th align="center" colspan="2" rowspan="1">G4</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Characteristic</th>
                        <th align="center" rowspan="1" colspan="1">Placebo</th>
                        <th align="center" rowspan="1" colspan="1">EMPA 10/25 mg</th>
                        <th align="center" rowspan="1" colspan="1">Placebo</th>
                        <th align="center" rowspan="1" colspan="1">EMPA 10/25 mg</th>
                        <th align="center" rowspan="1" colspan="1">Placebo</th>
                        <th align="center" rowspan="1" colspan="1">EMPA 10/25 mg</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic></td>
                        <td align="center" rowspan="1" colspan="1">519</td>
                        <td align="center" rowspan="1" colspan="1">1,003</td>
                        <td align="center" rowspan="1" colspan="1">277</td>
                        <td align="center" rowspan="1" colspan="1">445</td>
                        <td align="center" rowspan="1" colspan="1">52</td>
                        <td align="center" rowspan="1" colspan="1">71</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td>
                        <td align="center" rowspan="1" colspan="1">358 (69.0)</td>
                        <td align="center" rowspan="1" colspan="1">653 (65.1)</td>
                        <td align="center" rowspan="1" colspan="1">167 (60.3)</td>
                        <td align="center" rowspan="1" colspan="1">277 (62.2)</td>
                        <td align="center" rowspan="1" colspan="1">30 (57.7)</td>
                        <td align="center" rowspan="1" colspan="1">41 (57.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Age (years), mean ± SD</td>
                        <td align="center" rowspan="1" colspan="1">67.1 ± 8.1</td>
                        <td align="center" rowspan="1" colspan="1">67.1 ± 7.5</td>
                        <td align="center" rowspan="1" colspan="1">67.9 ± 8.2</td>
                        <td align="center" rowspan="1" colspan="1">67.7 ± 8.7</td>
                        <td align="center" rowspan="1" colspan="1">63.7 ± 10.7</td>
                        <td align="center" rowspan="1" colspan="1">68.8 ± 9.1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race,<bold><xref rid="tblfn2" ref-type="table-fn">*</xref></bold>
<italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td align="center" rowspan="1" colspan="1">369 (71.1)</td>
                        <td align="center" rowspan="1" colspan="1">730 (72.8)</td>
                        <td align="center" rowspan="1" colspan="1">195 (70.4)</td>
                        <td align="center" rowspan="1" colspan="1">308 (69.2)</td>
                        <td align="center" rowspan="1" colspan="1">24 (46.2)</td>
                        <td align="center" rowspan="1" colspan="1">47 (66.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td align="center" rowspan="1" colspan="1">118 (22.7)</td>
                        <td align="center" rowspan="1" colspan="1">210 (20.9)</td>
                        <td align="center" rowspan="1" colspan="1">70 (25.3)</td>
                        <td align="center" rowspan="1" colspan="1">109 (24.5)</td>
                        <td align="center" rowspan="1" colspan="1">28 (53.8)</td>
                        <td align="center" rowspan="1" colspan="1">22 (31.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black or African American</td>
                        <td align="center" rowspan="1" colspan="1">29 (5.6)</td>
                        <td align="center" rowspan="1" colspan="1">52 (5.2)</td>
                        <td align="center" rowspan="1" colspan="1">8 (2.9)</td>
                        <td align="center" rowspan="1" colspan="1">24 (5.4)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1 (1.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Not Hispanic or Latino</td>
                        <td align="center" rowspan="1" colspan="1">450 (86.7)</td>
                        <td align="center" rowspan="1" colspan="1">864 (86.1)</td>
                        <td align="center" rowspan="1" colspan="1">245 (88.4)</td>
                        <td align="center" rowspan="1" colspan="1">384 (86.3)</td>
                        <td align="center" rowspan="1" colspan="1">50 (96.2)</td>
                        <td align="center" rowspan="1" colspan="1">65 (91.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td align="center" rowspan="1" colspan="1">68 (13.1)</td>
                        <td align="center" rowspan="1" colspan="1">138 (13.8)</td>
                        <td align="center" rowspan="1" colspan="1">33 (11.6)</td>
                        <td align="center" rowspan="1" colspan="1">61 (13.7)</td>
                        <td align="center" rowspan="1" colspan="1">2 (3.8)</td>
                        <td align="center" rowspan="1" colspan="1">6 (8.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HbA<sub>1c</sub>, mean ± SD</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> %</td>
                        <td align="center" rowspan="1" colspan="1">8.0 ± 0.8</td>
                        <td align="center" rowspan="1" colspan="1">8.01 ± 0.8</td>
                        <td align="center" rowspan="1" colspan="1">8.1 ± 0.9</td>
                        <td align="center" rowspan="1" colspan="1">8.1 ± 0.9</td>
                        <td align="center" rowspan="1" colspan="1">8.1 ± 0.9</td>
                        <td align="center" rowspan="1" colspan="1">7.95 ± 0.91</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> mmol/mol</td>
                        <td align="center" rowspan="1" colspan="1">64 ± 9</td>
                        <td align="center" rowspan="1" colspan="1">64 ± 9</td>
                        <td align="center" rowspan="1" colspan="1">65 ± 10</td>
                        <td align="center" rowspan="1" colspan="1">65 ± 10</td>
                        <td align="center" rowspan="1" colspan="1">65 ± 10</td>
                        <td align="center" rowspan="1" colspan="1">63 ± 10</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean ± SD</td>
                        <td align="center" rowspan="1" colspan="1">30.6 ± 5.2</td>
                        <td align="center" rowspan="1" colspan="1">31.0 ± 5.5</td>
                        <td align="center" rowspan="1" colspan="1">31.1 ± 5.8</td>
                        <td align="center" rowspan="1" colspan="1">31.3 ± 5.6</td>
                        <td align="center" rowspan="1" colspan="1">30.9 ± 5.7</td>
                        <td align="center" rowspan="1" colspan="1">29.5 ± 4.9</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Blood pressure (mmHg),<xref rid="tblfn3" ref-type="table-fn">†</xref> mean ± SD</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Systolic</td>
                        <td align="center" rowspan="1" colspan="1">136.7 ± 18.7</td>
                        <td align="center" rowspan="1" colspan="1">135.9 ± 17.1</td>
                        <td align="center" rowspan="1" colspan="1">135.0 ± 17.7</td>
                        <td align="center" rowspan="1" colspan="1">137.4 ± 18.0</td>
                        <td align="center" rowspan="1" colspan="1">143.0 ± 23.9</td>
                        <td align="center" rowspan="1" colspan="1">137.5 ± 21.0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Diastolic</td>
                        <td align="center" rowspan="1" colspan="1">75.4 ± 10.2</td>
                        <td align="center" rowspan="1" colspan="1">75.5 ± 10.1</td>
                        <td align="center" rowspan="1" colspan="1">73.6 ± 10.2</td>
                        <td align="center" rowspan="1" colspan="1">74.0 ± 9.9</td>
                        <td align="center" rowspan="1" colspan="1">75.2 ± 12.4</td>
                        <td align="center" rowspan="1" colspan="1">72.6 ± 10.8</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Heart failure,<xref rid="tblfn4" ref-type="table-fn">‡</xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="center" rowspan="1" colspan="1">51 (9.8)</td>
                        <td align="center" rowspan="1" colspan="1">114 (11.4)</td>
                        <td align="center" rowspan="1" colspan="1">31 (11.2)</td>
                        <td align="center" rowspan="1" colspan="1">53 (11.9)</td>
                        <td align="center" rowspan="1" colspan="1">8 (15.4)</td>
                        <td align="center" rowspan="1" colspan="1">7 (9.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td>
                        <td align="center" rowspan="1" colspan="1">486 (93.6)</td>
                        <td align="center" rowspan="1" colspan="1">950 (94.7)</td>
                        <td align="center" rowspan="1" colspan="1">270 (97.5)</td>
                        <td align="center" rowspan="1" colspan="1">426 (95.7)</td>
                        <td align="center" rowspan="1" colspan="1">51 (98.1)</td>
                        <td align="center" rowspan="1" colspan="1">68 (95.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Concomitant medications, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Metformin</td>
                        <td align="center" rowspan="1" colspan="1">352 (67.8)</td>
                        <td align="center" rowspan="1" colspan="1">662 (66.0)</td>
                        <td align="center" rowspan="1" colspan="1">118 (42.6)</td>
                        <td align="center" rowspan="1" colspan="1">198 (44.5)</td>
                        <td align="center" rowspan="1" colspan="1">9 (17.3)</td>
                        <td align="center" rowspan="1" colspan="1">35 (49.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Insulin</td>
                        <td align="center" rowspan="1" colspan="1">268 (51.6)</td>
                        <td align="center" rowspan="1" colspan="1">502 (50.0)</td>
                        <td align="center" rowspan="1" colspan="1">172 (62.1)</td>
                        <td align="center" rowspan="1" colspan="1">276 (62.0)</td>
                        <td align="center" rowspan="1" colspan="1">38 (73.1)</td>
                        <td align="center" rowspan="1" colspan="1">53 (74.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ACE inhibitors/ARBs</td>
                        <td align="center" rowspan="1" colspan="1">424 (81.7)</td>
                        <td align="center" rowspan="1" colspan="1">843 (84.0)</td>
                        <td align="center" rowspan="1" colspan="1">224 (80.9)</td>
                        <td align="center" rowspan="1" colspan="1">361 (81.1)</td>
                        <td align="center" rowspan="1" colspan="1">36 (69.2)</td>
                        <td align="center" rowspan="1" colspan="1">51 (71.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Loop diuretics</td>
                        <td align="center" rowspan="1" colspan="1">109 (21)</td>
                        <td align="center" rowspan="1" colspan="1">195 (19.4)</td>
                        <td align="center" rowspan="1" colspan="1">91 (32.9)</td>
                        <td align="center" rowspan="1" colspan="1">151 (33.9)</td>
                        <td align="center" rowspan="1" colspan="1">24 (46.2)</td>
                        <td align="center" rowspan="1" colspan="1">35 (49.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Statins</td>
                        <td align="center" rowspan="1" colspan="1">370 (71.3)</td>
                        <td align="center" rowspan="1" colspan="1">752 (75.0)</td>
                        <td align="center" rowspan="1" colspan="1">198 (71.5)</td>
                        <td align="center" rowspan="1" colspan="1">315 (70.8)</td>
                        <td align="center" rowspan="1" colspan="1">40 (76.9)</td>
                        <td align="center" rowspan="1" colspan="1">52 (73.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Aspirin</td>
                        <td align="center" rowspan="1" colspan="1">387 (74.6)</td>
                        <td align="center" rowspan="1" colspan="1">739 (73.7)</td>
                        <td align="center" rowspan="1" colspan="1">209 (75.5)</td>
                        <td align="center" rowspan="1" colspan="1">333 (74.8)</td>
                        <td align="center" rowspan="1" colspan="1">34 (65.4)</td>
                        <td align="center" rowspan="1" colspan="1">51 (71.8)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>CKD categories by eGFR: G3A, 45 to &lt;60 mL/min/1.73 m<sup>2</sup>; G3B, 30 to &lt;45 mL/min/1.73 m<sup>2</sup>; G4, 15 to &lt;30 mL/min/1.73 m<sup>2</sup>. ARB, angiotensin receptor blocker; EMPA 10/25, empagliflozin 10 or 25 mg.</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>*</label>
                      <p>Race identified as other (American Indian, Alaska Native, Hawaiian, Pacific Islander) or race information not recorded for seven patients in the CKD category G3A group.</p>
                    </fn>
                    <fn id="tblfn3">
                      <label>†</label>
                      <p>Baseline systolic/diastolic blood pressure readings were missing for one patient in the empagliflozin 10 mg group.</p>
                    </fn>
                    <fn id="tblfn4">
                      <label>‡</label>
                      <p>A history of heart failure at baseline was identified by narrow standardized MedDRA query 20000004.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s12">
                <title>AEs</title>
                <p>Rates of SAEs and AEs leading to discontinuation were similar between the empagliflozin and placebo treatment groups across the overall cohort and CKD subgroups (<xref rid="T2" ref-type="table">Table 2</xref> and <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Fig. 1</ext-link>). SAE incidence rates were numerically higher in the G4 category for empagliflozin versus placebo (41.31 vs. 29.93 per 100 patient-years). However, numbers of patients in this group were low (51 and 71 patients, respectively), with wide CIs that should therefore be interpreted with caution.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Patients with at least one AE by CKD category at baseline</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="2" rowspan="1">Placebo</th>
                        <th align="center" colspan="2" rowspan="1">EMPA 10/25 mg</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Category</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">N</italic> (%)</th>
                        <th align="center" rowspan="1" colspan="1">Rate, 100 patient-years (95% CI)</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">N</italic> (%)</th>
                        <th align="center" rowspan="1" colspan="1">Rate, 100 patient-years (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1"> SAEs</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">1,204/4,904 (24.6)</td>
                        <td align="center" rowspan="1" colspan="1">18.61 (17.57–19.69)</td>
                        <td align="center" rowspan="1" colspan="1">2,161/10,177 (21.2)</td>
                        <td align="center" rowspan="1" colspan="1">15.52 (14.88–16.19)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">209/519 (40.3)</td>
                        <td align="center" rowspan="1" colspan="1">27.18 (23.62–31.12)</td>
                        <td align="center" rowspan="1" colspan="1">354/1,003 (35.3)</td>
                        <td align="center" rowspan="1" colspan="1">22.46 (20.19–24.93)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">113/277 (40.8)</td>
                        <td align="center" rowspan="1" colspan="1">31.16 (25.69–37.46)</td>
                        <td align="center" rowspan="1" colspan="1">177/445 (39.8)</td>
                        <td align="center" rowspan="1" colspan="1">26.81 (23.00–31.06)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">13/52 (25.0)</td>
                        <td align="center" rowspan="1" colspan="1">29.93 (15.94–51.17)</td>
                        <td align="center" rowspan="1" colspan="1">28/71 (39.4)</td>
                        <td align="center" rowspan="1" colspan="1">41.31 (27.46–59.69)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AEs leading to treatment discontinuation</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">565/4,904 (11.5)</td>
                        <td align="center" rowspan="1" colspan="1">7.40 (6.80–8.04)</td>
                        <td align="center" rowspan="1" colspan="1">1,033/10,177 (10.2)</td>
                        <td align="center" rowspan="1" colspan="1">6.43 (6.05–6.84)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">100/519 (19.3)</td>
                        <td align="center" rowspan="1" colspan="1">10.37 (8.44–12.61)</td>
                        <td align="center" rowspan="1" colspan="1">179/1,003 (17.8)</td>
                        <td align="center" rowspan="1" colspan="1">9.26 (7.95–10.72)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">62/277 (22.4)</td>
                        <td align="center" rowspan="1" colspan="1">13.10 (10.05–16.79)</td>
                        <td align="center" rowspan="1" colspan="1">113/445 (25.4)</td>
                        <td align="center" rowspan="1" colspan="1">14.17 (11.68–17.03)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">10/52 (19.2)</td>
                        <td align="center" rowspan="1" colspan="1">21.47 (10.30–39.47)</td>
                        <td align="center" rowspan="1" colspan="1">14/71 (19.7)</td>
                        <td align="center" rowspan="1" colspan="1">15.70 (8.59–26.35)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypoglycemia</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">1,045/4,904 (21.3)</td>
                        <td align="center" rowspan="1" colspan="1">16.32 (15.35–17.34)</td>
                        <td align="center" rowspan="1" colspan="1">2,067/10,177 (20.3)</td>
                        <td align="center" rowspan="1" colspan="1">15.69 (15.02–16.38)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">177/519 (34.1)</td>
                        <td align="center" rowspan="1" colspan="1">24.02 (20.62–27.83)</td>
                        <td align="center" rowspan="1" colspan="1">268/1,003 (26.7)</td>
                        <td align="center" rowspan="1" colspan="1">17.20 (15.21–19.39)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">91/277 (32.9)</td>
                        <td align="center" rowspan="1" colspan="1">24.23 (19.51–29.75)</td>
                        <td align="center" rowspan="1" colspan="1">141/445 (31.7)</td>
                        <td align="center" rowspan="1" colspan="1">22.85 (19.24–26.95)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">23/52 (44.2)</td>
                        <td align="center" rowspan="1" colspan="1">67.50 (42.80–101.23)</td>
                        <td align="center" rowspan="1" colspan="1">24/71 (33.8)</td>
                        <td align="center" rowspan="1" colspan="1">39.34 (25.21–58.52)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Urinary tract infection</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">691/4,904 (14.1)</td>
                        <td align="center" rowspan="1" colspan="1">9.70 (8.99–10.46)</td>
                        <td align="center" rowspan="1" colspan="1">1,382/10,177 (13.6)</td>
                        <td align="center" rowspan="1" colspan="1">9.27 (8.79–9.77)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">84/519 (16.2)</td>
                        <td align="center" rowspan="1" colspan="1">9.18 (7.32–11.37)</td>
                        <td align="center" rowspan="1" colspan="1">200/1,003 (19.9)</td>
                        <td align="center" rowspan="1" colspan="1">11.36 (9.84–13.05)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">62/277 (22.4)</td>
                        <td align="center" rowspan="1" colspan="1">13.69 (10.49–17.54)</td>
                        <td align="center" rowspan="1" colspan="1">101/445 (22.7)</td>
                        <td align="center" rowspan="1" colspan="1">13.98 (11.39–16.99)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">5/52 (9.6)</td>
                        <td align="center" rowspan="1" colspan="1">10.24 (3.32–23.89)</td>
                        <td align="center" rowspan="1" colspan="1">18/71 (25.4)</td>
                        <td align="center" rowspan="1" colspan="1">25.19 (14.93–39.81)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Genital infection</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">75/4,904 (1.5)</td>
                        <td align="center" rowspan="1" colspan="1">0.85 (0.75–1.20)</td>
                        <td align="center" rowspan="1" colspan="1">565/10,177 (5.6)</td>
                        <td align="center" rowspan="1" colspan="1">3.54 (3.25–3.84)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">8/519 (1.5)</td>
                        <td align="center" rowspan="1" colspan="1">0.79 (0.34–1.56)</td>
                        <td align="center" rowspan="1" colspan="1">54/1,003 (5.4)</td>
                        <td align="center" rowspan="1" colspan="1">2.75 (2.06–3.58)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">2/277 (0.7)</td>
                        <td align="center" rowspan="1" colspan="1">0.39 (0.05–1.43)</td>
                        <td align="center" rowspan="1" colspan="1">15/445 (3.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.78 (1.00–2.94)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">0/52 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1/71 (1.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.13 (0.03–6.28)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Volume depletion</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">147/4,904 (3.0)</td>
                        <td align="center" rowspan="1" colspan="1">1.89 (1.60–2.23)</td>
                        <td align="center" rowspan="1" colspan="1">320/10,177 (3.1)</td>
                        <td align="center" rowspan="1" colspan="1">1.97 (1.76–2.20)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">33/519 (6.4)</td>
                        <td align="center" rowspan="1" colspan="1">3.38 (2.32–4.74)</td>
                        <td align="center" rowspan="1" colspan="1">63/1,003 (6.2)</td>
                        <td align="center" rowspan="1" colspan="1">3.22 (2.48–4.12)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">19/277 (6.9)</td>
                        <td align="center" rowspan="1" colspan="1">3.95 (2.38–6.17)</td>
                        <td align="center" rowspan="1" colspan="1">28/445 (6.3)</td>
                        <td align="center" rowspan="1" colspan="1">3.43 (2.28–4.95)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">6/52 (11.5)</td>
                        <td align="center" rowspan="1" colspan="1">12.04 (4.42–26.19)</td>
                        <td align="center" rowspan="1" colspan="1">7/71 (9.8)</td>
                        <td align="center" rowspan="1" colspan="1">8.22 (3.30–16.93)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Edema</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">278/4,904 (5.7)</td>
                        <td align="center" rowspan="1" colspan="1">3.67 (3.25–4.12)</td>
                        <td align="center" rowspan="1" colspan="1">269/10,177 (2.6)</td>
                        <td align="center" rowspan="1" colspan="1">1.65 (1.46–1.86)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">51/519 (9.8)</td>
                        <td align="center" rowspan="1" colspan="1">5.37 (4.00–7.06)</td>
                        <td align="center" rowspan="1" colspan="1">49/1003 (4.9)</td>
                        <td align="center" rowspan="1" colspan="1">2.48 (1.84–3.28)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">38/277 (13.7)</td>
                        <td align="center" rowspan="1" colspan="1">8.12 (5.75–11.15)</td>
                        <td align="center" rowspan="1" colspan="1">36/445 (8.1)</td>
                        <td align="center" rowspan="1" colspan="1">4.42 (3.10–6.12)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">5/52 (9.6)</td>
                        <td align="center" rowspan="1" colspan="1">11.77 (3.82–27.47)</td>
                        <td align="center" rowspan="1" colspan="1">1/71 (1.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.11 (0.03–6.18)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Bone fracture</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">134/4,904 (2.7)</td>
                        <td align="center" rowspan="1" colspan="1">1.72 (1.44–2.04)</td>
                        <td align="center" rowspan="1" colspan="1">233/10,177 (2.3)</td>
                        <td align="center" rowspan="1" colspan="1">1.42 (1.25–1.62)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">26/519 (5.0)</td>
                        <td align="center" rowspan="1" colspan="1">2.60 (1.79–3.81)</td>
                        <td align="center" rowspan="1" colspan="1">37/1,003 (3.7)</td>
                        <td align="center" rowspan="1" colspan="1">1.86 (1.31–2.56)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">12/277 (4.3)</td>
                        <td align="center" rowspan="1" colspan="1">2.40 (1.24–4.19)</td>
                        <td align="center" rowspan="1" colspan="1">20/445 (4.5)</td>
                        <td align="center" rowspan="1" colspan="1">2.40 (1.46–3.70)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">1/52 (1.9)</td>
                        <td align="center" rowspan="1" colspan="1">2.06 (0.05–11.49)</td>
                        <td align="center" rowspan="1" colspan="1">0/71 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Falls</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">87/4,904 (1.8)</td>
                        <td align="center" rowspan="1" colspan="1">1.11 (0.89–1.37)</td>
                        <td align="center" rowspan="1" colspan="1">197/10,177 (1.9)</td>
                        <td align="center" rowspan="1" colspan="1">1.20 (1.04–1.38)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">17/519 (3.3)</td>
                        <td align="center" rowspan="1" colspan="1">1.70 (0.99–2.72)</td>
                        <td align="center" rowspan="1" colspan="1">30/1,003 (3.0)</td>
                        <td align="center" rowspan="1" colspan="1">1.50 (1.01–2.15)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">10/277 (3.6)</td>
                        <td align="center" rowspan="1" colspan="1">2.01 (0.97–3.70)</td>
                        <td align="center" rowspan="1" colspan="1">11/445 (2.5)</td>
                        <td align="center" rowspan="1" colspan="1">1.30 (0.65–2.33)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">1/52 (1.9)</td>
                        <td align="center" rowspan="1" colspan="1">2.06 (0.05–11.49)</td>
                        <td align="center" rowspan="1" colspan="1">1/71 (1.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.11 (0.03–6.18)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hyperkalemia</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">90/4,904 (1.8)</td>
                        <td align="center" rowspan="1" colspan="1">1.15 (0.92–1.41)</td>
                        <td align="center" rowspan="1" colspan="1">119/10,177 (1.2)</td>
                        <td align="center" rowspan="1" colspan="1">0.72 (0.60–0.86)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">23/519 (4.4)</td>
                        <td align="center" rowspan="1" colspan="1">2.31 (1.47–3.47)</td>
                        <td align="center" rowspan="1" colspan="1">37/1,003 (3.7)</td>
                        <td align="center" rowspan="1" colspan="1">1.86 (1.31–2.56)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">18/277 (7.6)</td>
                        <td align="center" rowspan="1" colspan="1">3.73 (2.21–5.89)</td>
                        <td align="center" rowspan="1" colspan="1">15/445 (3.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.78 (1.00–2.93)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">3/52 (6)</td>
                        <td align="center" rowspan="1" colspan="1">6.16 (1.27–17.99)</td>
                        <td align="center" rowspan="1" colspan="1">1/71 (1.4)</td>
                        <td align="center" rowspan="1" colspan="1">1.11 (0.03–6.21)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ARF</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">169/4,904 (3.4)</td>
                        <td align="center" rowspan="1" colspan="1">2.18 (1.86–2.53)</td>
                        <td align="center" rowspan="1" colspan="1">291/10,177 (1.2)</td>
                        <td align="center" rowspan="1" colspan="1">1.78 (1.58–2.00)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">48/519 (9.2)</td>
                        <td align="center" rowspan="1" colspan="1">4.92 (3.63–6.53)</td>
                        <td align="center" rowspan="1" colspan="1">86/1,003 (8.6)</td>
                        <td align="center" rowspan="1" colspan="1">4.44 (3.55–5.48)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">37/277 (13.3)</td>
                        <td align="center" rowspan="1" colspan="1">7.85 (5.53–10.83)</td>
                        <td align="center" rowspan="1" colspan="1">57/445 (12.8)</td>
                        <td align="center" rowspan="1" colspan="1">7.22 (5.47–9.35)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">6/52 (11.5)</td>
                        <td align="center" rowspan="1" colspan="1">13.87 (5.09–30.19)</td>
                        <td align="center" rowspan="1" colspan="1">9/71 (12.7)</td>
                        <td align="center" rowspan="1" colspan="1">10.85 (4.96–20.59)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Lower limb amputation<xref rid="tblfn6" ref-type="table-fn">*</xref></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Overall</td>
                        <td align="center" rowspan="1" colspan="1">46/4,904 (0.9)</td>
                        <td align="center" rowspan="1" colspan="1">0.52 (0.38–0.69)</td>
                        <td align="center" rowspan="1" colspan="1">95/10,177 (0.1)</td>
                        <td align="center" rowspan="1" colspan="1">0.52 (0.42–0.63)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3A</td>
                        <td align="center" rowspan="1" colspan="1">11/519 (2.1)</td>
                        <td align="center" rowspan="1" colspan="1">0.92 (0.46–1.65)</td>
                        <td align="center" rowspan="1" colspan="1">17/1,003 (1.7)</td>
                        <td align="center" rowspan="1" colspan="1">0.74 (0.43–1.18)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G3B</td>
                        <td align="center" rowspan="1" colspan="1">7/277 (2.5)</td>
                        <td align="center" rowspan="1" colspan="1">1.22 (0.49–2.51)</td>
                        <td align="center" rowspan="1" colspan="1">10/445 (2.2)</td>
                        <td align="center" rowspan="1" colspan="1">0.95 (0.46–1.75)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> G4</td>
                        <td align="center" rowspan="1" colspan="1">0/52 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">4/71 (5.6)</td>
                        <td align="center" rowspan="1" colspan="1">3.59 (0.98–9.20)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn5">
                      <p>Exposure-adjusted incidence rates were calculated per 100 patient-years as 100 × <italic toggle="yes">n</italic> / T, where <italic toggle="yes">n</italic> was the number of participants with the event and T the total patient-years at risk for the event. Patient-years at risk were defined as the time from the first dose of study treatment to the onset of the first event (for patients with an event) or to the last dose plus 7 days (for those without an event). The eGFR was calculated using the CKD-EPI equation. CKD categories by eGFR: G3A, 45 to &lt;60 mL/min/1.73 m<sup>2</sup>; G3B, 30 to &lt;45 mL/min/1.73 m<sup>2</sup>; G4, 15 to &lt;30 mL/min/1.73 m<sup>2</sup>. Frequencies <italic toggle="yes">n</italic>/<italic toggle="yes">N</italic> = patients with one or more events of all patients who received one or more doses of study drug. EMPA 10/25, empagliflozin 10 or 25 mg.</p>
                    </fn>
                    <fn id="tblfn6">
                      <label>*</label>
                      <p>Data from the EMPA-REG OUTCOME trial only. No amputations were reported for the four patients with missing baseline eGFR values.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Events of special interest (including lower limb amputations and ARF) were similar between empagliflozin and placebo across CKD subgroups and overall (<xref rid="T2" ref-type="table">Table 2</xref> and <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Fig. 1</ext-link>). An exception was the frequency of genital infections, which was higher among those receiving empagliflozin compared with placebo. Notably, the incidence rates of genital infections were progressively lower across CKD categories 3A, 3B, and 4. In contrast, most other AEs were more frequent among those with worsening CKD categories. Unadjusted time to first occurrence of ARF, volume depletion, and bone fracture revealed no significant differences between treatment groups, while edema was less common in patients receiving empagliflozin versus placebo (<xref rid="F1" ref-type="fig">Fig. 1</xref> and <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Fig. 2</ext-link>). For adjusted Cox regression models, the G4 group was too small for statistical analyses and was therefore combined with the G3B group (CKD categories G3B–G4). Similar risks for volume depletion and ARF persisted with adjustment for empagliflozin and placebo in the groups with eGFR &lt;45 mL/min/1.73 m<sup>2</sup> (CKD categories G3B–G4) and 45 to &lt;60 mL/min/1.73 m<sup>2</sup> (CKD category G3A), but lower risks were observed with empagliflozin for hyperkalemia (hazard ratio [HR] 0.59 [95% CI 0.37–0.96, <italic toggle="yes">P</italic> = 0.0323] and 0.48 [0.26–0.91], <italic toggle="yes">P</italic> = 0.0243, respectively) and edema (0.47 [0.33–0.68, <italic toggle="yes">P</italic> &lt; 0.0001] and 0.44 [0.28–0.68, <italic toggle="yes">P</italic> = 0.0002], respectively) compared with placebo (<ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Table 3</ext-link>). Testing for heterogeneity across trials showed nominal differences with regard to the HRs and 95% CIs for the risks of volume depletion, ARF, hyperkalemia, and edema (<ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">Supplementary Tables 4</ext-link> and <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">5</ext-link>). Even though the EMPA-REG OUTCOME trial versus other trials showed a statistically significant different trial effect for volume depletion (<italic toggle="yes">P</italic> &lt; 0.001) and edema (<italic toggle="yes">P</italic> = 0.005), which can give a hint that there might be trial-specific heterogeneity, the HRs were essentially identical compared with the original Cox regression model or with the additional trial frailty term model including study as a random effect (for eGFR 45 &lt; 60 mL/min/1.73 m<sup>2</sup> for volume depletion: HR 0.90 [original model] vs. 0.90 [EMPA-REG OUTCOME trial vs. other] and 0.91 [frailty term model with trial as random effect]; for edema: 0.47 vs. 0.47 and 0.47, respectively).</p>
                <fig position="float" id="F1" fig-type="figure">
                  <label>Figure 1</label>
                  <caption>
                    <p>Kaplan-Meier estimates of time to first event of hyperkalemia (<italic toggle="yes">A</italic>), volume depletion (<italic toggle="yes">B</italic>), edema (<italic toggle="yes">C</italic>), and ARF (<italic toggle="yes">D</italic>) in patients with eGFR &lt;45 mL/min/1.73 m<sup>2</sup> (left) and 45 to &lt;60 mL/min/1.73 m<sup>2</sup> (right). eGFR was calculated using the CKD-EPI equation.</p>
                  </caption>
                  <graphic xlink:href="dc212034f1" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="s13">
              <title>Conclusions</title>
              <p>This comprehensive safety analysis of a large pool of patients with advanced CKD who received empagliflozin in clinical trials found no overall differences in rates of SAEs, AEs leading to discontinuation, or events of special interest with empagliflozin treatment versus placebo, irrespective of baseline eGFR. An exception was genital infections, a well-recognized adverse effect of the SGLT2 inhibitor class (<xref rid="B16" ref-type="bibr">16</xref>–<xref rid="B18" ref-type="bibr">18</xref>), which occurred more frequently in the empagliflozin group versus the placebo group but with lower incidence rates in advanced CKD categories. This could be due to, at least in part, lesser urinary glucose excretion at lower levels of eGFR (<xref rid="B19" ref-type="bibr">19</xref>). Indeed, poorly controlled diabetes, typically accompanied by higher urinary glucose excretion, independently increases the risk of genital infections in patients with type 2 diabetes (<xref rid="B20" ref-type="bibr">20</xref>). Current prescribing information for empagliflozin notes that a higher incidence of AEs related to reduced renal function may be seen in patients with CKD (<xref rid="B9" ref-type="bibr">9</xref>). However, while ARF and other AEs were more common with decreasing kidney function in both treatment groups, observed rates were similar between empagliflozin and placebo in all CKD categories. Notably, a meta-analysis of SGLT2 inhibitor studies, which included cardiovascular outcome trials and the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial that was conducted in patients with type 2 diabetes and CKD, demonstrated a 25% reduction in the risk of acute kidney injury (<xref rid="B21" ref-type="bibr">21</xref>).</p>
              <p>The safety findings with empagliflozin in this pooled analysis may support the use of SGLT2 inhibitors in patients with type 2 diabetes and advanced CKD. In CREDENCE (<xref rid="B22" ref-type="bibr">22</xref>), canagliflozin showed consistent benefit across CKD subgroups. The Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) trial (<xref rid="B23" ref-type="bibr">23</xref>) further demonstrated that dapagliflozin reduced risks of CKD outcomes, as well as heart failure events, cardiovascular death, and all-cause mortality, in a trial population of patients with CKD, one-third of whom did not have type 2 diabetes. The American Diabetes Association (<xref rid="B24" ref-type="bibr">24</xref>) currently recommends that for patients with type 2 diabetes, CKD, and albuminuria, SGLT2 inhibitor therapy is preferred but that either an SGLT2 inhibitor or a glucagon-like peptide 1 receptor agonist is suitable for patients with type 2 diabetes and CKD in the absence of albuminuria. The Kidney Disease: Improving Global Outcomes guidelines for diabetes and CKD (<xref rid="B25" ref-type="bibr">25</xref>) also recommended an SGLT2 inhibitor as first-line treatment in patients with CKD and type 2 diabetes who have an eGFR ≥30 mL/min/1.73 m<sup>2</sup>, regardless of the presence or absence of albuminuria. However, the current label recommendations for eGFR levels at which SGLT2 inhibitors can be initiated or should be discontinued differ between agents, and the labeling for each agent may differ between countries and regions. Of note, no new safety concerns were seen in the small group of patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> included in this analysis, supporting the safety of SGLT2 inhibitors in advanced CKD. This aligns with findings from the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR-Reduced) that included patients with heart failure and eGFR level as low as 20 mL/min/1.73 m<sup>2</sup> (<xref rid="B10" ref-type="bibr">10</xref>). CKD was present in 53% of this trial population.</p>
              <p>Patients with advanced CKD, especially those receiving renin-angiotensin system blockers, are prone to hyperkalemia. Notably, a lower risk for hyperkalemia was observed in patients receiving empagliflozin versus placebo in the present analysis. Dapagliflozin has also shown no signal for higher risk of hyperkalemia (<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>). Moreover, hyperkalemia risk was mitigated by canagliflozin in the CREDENCE trial, and there were no meaningful effects of canagliflozin on serum potassium or related AEs across the Canagliflozin Cardiovascular Assessment Study (CANVAS) program (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>). This favorable effect of SGLT2 inhibitors on serum potassium in patients with type 2 diabetes and CKD might permit the broader use of drugs associated with hyperkalemia, such as mineralocorticoid receptor antagonists (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>).</p>
              <p>In the pooled data set analyzed for the current study, there was no association between empagliflozin and increased risk of bone fracture or lower limb amputations. The pattern for these events with empagliflozin was similar to that seen with placebo. Indeed, a similar risk of volume depletion and ARF was seen in the empagliflozin and placebo groups in this analysis, but a reduction in the occurrence of edema was reported in patients receiving empagliflozin versus those in the placebo group. Like empagliflozin, no causal association between dapagliflozin and risk of fractures or lower limb amputations has been confirmed (<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>). However, the CANVAS program reported a twofold increased risk of lower limb amputation and a 26% increased risk of bone fractures associated with canagliflozin (<xref rid="B32" ref-type="bibr">32</xref>). While this initially resulted in a black box warning to highlight the potentially increased risk of lower limb amputation for canagliflozin (<xref rid="B18" ref-type="bibr">18</xref>), these findings were not reproduced in the subsequent CREDENCE trial, and the black box warning has since been removed (<xref rid="B33" ref-type="bibr">33</xref>).</p>
              <p>In this pooled safety analysis, we did not assess diabetic ketoacidosis by CKD subgroup because the incidence of this AE was too low. However, in a previous pooled analysis, overall observed rates of diabetic ketoacidosis were comparable across empagliflozin and placebo treatment groups (<xref rid="B14" ref-type="bibr">14</xref>). A similar result was seen in the DAPA-CKD trial, where diabetic ketoacidosis was not seen in any participant receiving dapagliflozin and was reported in only two receiving placebo (<xref rid="B23" ref-type="bibr">23</xref>).</p>
              <p>Strengths of this analysis include the large sample size and inclusion of only patients randomly assigned to double-blind treatment. The data set was derived from placebo-controlled clinical trials at different stages of development, and it included patients in each of the low eGFR categories for analysis. Baseline characteristics were balanced between the different treatment groups, and time on treatment was similar. Limitations of this pooled analysis arose from the varying durations, designs, and populations of the included studies. However, this limitation applies to all pooled analyses, including meta-analyses. In turn, it is generally accepted that the increased number of trials/individuals in pooled analyses outweigh the limitations mentioned above. Additionally, by merging the patients treated with empagliflozin 10 mg or 25 mg into a single group, this analysis cannot elaborate on potential dose effects for AEs or SAEs. In other studies, however, the safety profile was similar for both doses (<xref rid="B14" ref-type="bibr">14</xref>). There were two studies (contributing a total of 432 participants) in which the dose of empagliflozin was escalated from 10 to 25 mg daily (NCT02182830: 157 participants) or uptitrated from 10 to 25 mg in patients with insufficient glycemic control only (NCT02453555: 275 participants). Data from these participants are included in the EMPA-REG OUTCOME 10 and 25 mg results. Renal impairment as an exclusion criterion at baseline in both these trials was defined as eGFR &lt;45 mL/min/1.73 m<sup>2</sup> compared with &lt;30 mL/min/1.73 m<sup>2</sup> in EMPA-REG OUTCOME. Findings regarding patients with CKD category G4 should be interpreted with caution because of the small sample size. Finally, statistical analyses were not adjusted for multiple comparisons.</p>
              <p>In conclusion, use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on development of hyperkalemia and edema. Dedicated SGLT2 inhibitor trials investigating treatment effects in patients with CKD may provide further data to confirm these observations, particularly in those with CKD category G4 where data are currently limited. Nevertheless, careful consideration of the current prescribing information for empagliflozin is recommended in this population. To build on the promising findings to date, a dedicated kidney disease outcome trial of empagliflozin versus placebo, enrolling &gt;6,600 patients with and without diabetes, including those with low levels of kidney function with and without albuminuria, is under way (EMPA-KIDNEY; NCT03594110) (<xref rid="B7" ref-type="bibr">7</xref>).</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Article Information</title>
              <p><bold>Acknowledgments.</bold> The authors thank Audrey Koitka-Weber, an employee of Boehringer Ingelheim at the time of the research, for her contributions to the analysis. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Andy Shepherd of Envision Scientific Solutions.</p>
              <p><bold>Funding and Duality of Interest.</bold> This pooled analysis was funded by the Boehringer Ingelheim &amp; Eli Lilly and Company Diabetes Alliance. K.R.T. is supported by National Institutes of Health National Center for Advancing Translational Sciences grant 4UL1TR00426-10 and National Institute of Diabetes and Digestive and Kidney Disease grants 1U2CDK114886-01, 5UM1DK100846-03, 2U01DK10086-07, 1U54DK083912, and 2UC4DK101108-02 and Centers for Disease Control and Prevention grant 75D301-19-Q-69877. She also has served as a consultant or advisor for Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca, Gilead, Goldfinch Bio, Novo Nordisk, Bayer, and Janssen. A.L. has received research support from Amgen, AstraZeneca, Janssen, Merck, Otsuka, Canadian Institute for Health Research, Kidney Foundation of Canada, Heart and Stroke Foundation of Canada, and the Michael Smith Health Research Foundation. M.N. has received lecture fees from Kyowa Kirin, Astellas Pharma, GlaxoSmithKline, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Torii, JT Pharma, Alexion, Akebia, MSD, and Boehringer Ingelheim and research support from JT Pharma, Kyowa Kirin, Astellas Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Torii, Kissei Pharmaceutical, and Boehringer Ingelheim. T.K. reports consulting/lecture fees from Abbott, Asahi Mutual Life Insurance, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Cosmic, Daiichi Sankyo, Eli Lilly and Company, Fujifilm, Fujirebio, Johnson &amp; Johnson, Kissei Pharmaceutical, Kowa Co., Kyowa Kirin, Medical Review, Medscape Education, Medtronic Sofamor Danek, Mitsubishi Tanabe Pharma, MSD, Musashino Foods, Nipro Pharma, Novartis International AG, Novo Nordisk, Ono Pharmaceutical, Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon, Taisho Pharmaceutical, Takeda Pharmaceutical, and Terumo; grants from Astellas Pharma, Daiichi Sankyo, Eli Lilly, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk, Ono Pharmaceutical, Sanofi, Sumitomo Dainippon, Taisho Pharmaceutical, and Takeda Pharmaceutical; contracted research from AstraZeneca and Takeda Pharmaceutical; joint research from Daiichi Sankyo; and an endowed chair from Asahi Mutual Life Insurance, Boehringer Ingelheim, Kowa Co., Mitsubishi Tanabe Pharma, MSD, Novo Nordisk, Ono Pharmaceutical, and Takeda Pharmaceutical. R.A. is supported by National Institutes of Health research grants 5R01HL126903 and VA 5I01 CX001753 and has served as a consultant for Boehringer Ingelheim, Bayer, Akebia, AstraZeneca, Reata, Relypsa, Chinook, and Janssen. S.J.H., A.E., I.R., and D.S. are employees of Boehringer Ingelheim. C.W. has received honoraria for consultancy and lecturing from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Merck Sharp &amp; Dohme, Mundipharma, Sanofi Genzyme, and Takeda Pharmaceutical. D.W. has received honoraria and consultancy fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Napp, Mundipharma, Mitsubishi, Ono Pharmaceutical, Pharmacosmos, Reata, and Vifor Fresenius. No other potential conflicts of interest relevant to this article were reported.</p>
              <p><bold>Author Contributions.</bold> K.R.T. and D.C.W. reviewed and edited the initial research proposal, reviewed the data and analysis, and reviewed and edited the manuscript. A.L., M.N., T.K., R.A., S.J.H., I.R., and C.W. reviewed and edited the initial research proposal and the manuscript. A.E. conducted the statistical analysis and reviewed and edited the manuscript. D.S. reviewed the data and analysis and reviewed and edited the manuscript. D.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
              <p><bold>Prior Presentation.</bold> Parts of this study were presented in abstract form at the 77th Scientific Sessions of the American Diabetes Association, San Diego, CA, 9–13 June 2017.</p>
            </ack>
            <fn-group>
              <fn>
                <p>Clinical trial reg. nos. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00885118?term=NCT00885118&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT00885118</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00789035?term=NCT00789035&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT00789035</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00558571?term=NCT00558571&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT00558571</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00749190?term=NCT00749190&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT00749190</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01011868?term=NCT01011868&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01011868</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01193218?term=NCT01193218&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01193218</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01210001?term=NCT01210001&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01210001</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01177813?term=NCT01177813&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01177813</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01159600?term=NCT01159600&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01159600</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01289990?term=NCT01289990&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01289990</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01131676?term=NCT01131676&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01131676</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01164501?term=NCT01164501&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01164501</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01370005?term=NCT01370005&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01370005</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01306214?term=NCT01306214&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01306214</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01649297?term=NCT01649297&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01649297</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01947855?term=NCT01947855&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT01947855</ext-link>, and <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02589639?term=NCT02589639&amp;draw=2&amp;rank=1" ext-link-type="uri">NCT02589639</ext-link>, <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link>.</p>
              </fn>
              <fn fn-type="supplementary-material">
                <p>This article contains supplementary material online at <ext-link xlink:href="https://doi.org/10.2337/figshare.19465484" ext-link-type="uri">https://doi.org/10.2337/figshare.19465484</ext-link>.</p>
              </fn>
              <fn>
                <p>This article is featured in a podcast available at <ext-link xlink:href="https://diabetesjournals.org/journals/pages/diabetes-core-update-podcasts" ext-link-type="uri">diabetesjournals.org/journals/pages/diabetes-core-update-podcasts</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alicic</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Rooney</surname><given-names>MT</given-names></string-name>, <string-name><surname>Tuttle</surname><given-names>KR</given-names></string-name></person-group>. <article-title>Diabetic kidney disease: challenges, progress, and possibilities</article-title>. <source>Clin J Am Soc Nephrol</source><year>2017</year>;<volume>12</volume>:<fpage>2032</fpage>–<lpage>2045</lpage><pub-id pub-id-type="pmid">28522654</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailey</surname><given-names>RA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>V</given-names></string-name>, <string-name><surname>Rupnow</surname><given-names>MF</given-names></string-name></person-group>. <article-title>Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: improving Global Outcomes (KDIGO) staging</article-title>. <source>BMC Res Notes</source><year>2014</year>;<volume>7</volume>:<fpage>415</fpage><pub-id pub-id-type="pmid">24990184</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Cosmo</surname><given-names>S</given-names></string-name>, <string-name><surname>Viazzi</surname><given-names>F</given-names></string-name>, <string-name><surname>Pacilli</surname><given-names>A</given-names></string-name>, <etal/>.; <collab>AMD-Annals Study Group</collab></person-group>. <article-title>Predictors of chronic kidney disease in type 2 diabetes: a longitudinal study from the AMD Annals initiative</article-title>. <source>Medicine (Baltimore)</source><year>2016</year>;<volume>95</volume>:<fpage>e4007</fpage><pub-id pub-id-type="pmid">27399078</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group</collab></person-group>. <article-title>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</article-title>. <source>Kidney Int Suppl</source><year>2013</year>;<volume>3</volume>:<fpage>1</fpage>–<lpage>150</lpage></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>United States Renal Data System</collab></person-group>. <article-title>2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States</article-title>. <comment>Accessed 21 April 2022. Available from <ext-link xlink:href="https://www.usrds.org/annual-data-report" ext-link-type="uri">https://www.usrds.org/annual-data-report</ext-link></comment></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matsushita</surname><given-names>K</given-names></string-name>, <string-name><surname>van der Velde</surname><given-names>M</given-names></string-name>, <string-name><surname>Astor</surname><given-names>BC</given-names></string-name>, <etal/>.; <collab>Chronic Kidney Disease Prognosis Consortium</collab></person-group>. <article-title>Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis</article-title>. <source>Lancet</source><year>2010</year>;<volume>375</volume>:<fpage>2073</fpage>–<lpage>2081</lpage><pub-id pub-id-type="pmid">20483451</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name><surname>Chertow</surname><given-names>GM</given-names></string-name>, <string-name><surname>Fan</surname><given-names>D</given-names></string-name>, <string-name><surname>McCulloch</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>CY</given-names></string-name></person-group>. <article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title>. <source>N Engl J Med</source><year>2004</year>;<volume>351</volume>:<fpage>1296</fpage>–<lpage>1305</lpage><pub-id pub-id-type="pmid">15385656</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barnett</surname><given-names>AH</given-names></string-name>, <string-name><surname>Mithal</surname><given-names>A</given-names></string-name>, <string-name><surname>Manassie</surname><given-names>J</given-names></string-name>, <etal/>.; <collab>EMPA-REG RENAL Trial Investigators</collab></person-group>. <article-title>Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2014</year>;<volume>2</volume>:<fpage>369</fpage>–<lpage>384</lpage><pub-id pub-id-type="pmid">24795251</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>JARDIANCE [package insert]</collab></person-group>. <publisher-loc>Burlington, ON, Canada</publisher-loc>, <publisher-name>Boehringer Ingelheim (Canada) Ltd.</publisher-name>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Packer</surname><given-names>M</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <etal/>.; <collab>EMPEROR-Reduced Trial Investigators</collab></person-group>. <article-title>Cardiovascular and renal outcomes with empagliflozin in heart failure</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>1413</fpage>–<lpage>1424</lpage><pub-id pub-id-type="pmid">32865377</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zinman</surname><given-names>B</given-names></string-name>, <string-name><surname>Wanner</surname><given-names>C</given-names></string-name>, <string-name><surname>Lachin</surname><given-names>JM</given-names></string-name>, <etal/>.; <collab>EMPA-REG OUTCOME Investigators</collab></person-group>. <article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>373</volume>:<fpage>2117</fpage>–<lpage>2128</lpage><pub-id pub-id-type="pmid">26378978</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wanner</surname><given-names>C</given-names></string-name>, <string-name><surname>Inzucchi</surname><given-names>SE</given-names></string-name>, <string-name><surname>Lachin</surname><given-names>JM</given-names></string-name>, <etal/>.; <collab>EMPA-REG OUTCOME Investigators</collab></person-group>. <article-title>Empagliflozin and progression of kidney disease in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>375</volume>:<fpage>323</fpage>–<lpage>334</lpage><pub-id pub-id-type="pmid">27299675</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wanner</surname><given-names>C</given-names></string-name>, <string-name><surname>Lachin</surname><given-names>JM</given-names></string-name>, <string-name><surname>Inzucchi</surname><given-names>SE</given-names></string-name>, <etal/>.; <collab>EMPA-REG OUTCOME Investigators</collab></person-group>. <article-title>Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease</article-title>. <source>Circulation</source><year>2018</year>;<volume>137</volume>:<fpage>119</fpage>–<lpage>129</lpage><pub-id pub-id-type="pmid">28904068</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kohler</surname><given-names>S</given-names></string-name>, <string-name><surname>Zeller</surname><given-names>C</given-names></string-name>, <string-name><surname>Iliev</surname><given-names>H</given-names></string-name>, <string-name><surname>Kaspers</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials</article-title>. <source>Adv Ther</source><year>2017</year>;<volume>34</volume>:<fpage>1707</fpage>–<lpage>1726</lpage><pub-id pub-id-type="pmid">28631216</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Inzucchi</surname><given-names>SE</given-names></string-name>, <string-name><surname>Iliev</surname><given-names>H</given-names></string-name>, <string-name><surname>Pfarr</surname><given-names>E</given-names></string-name>, <string-name><surname>Zinman</surname><given-names>B</given-names></string-name></person-group>. <article-title>Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial</article-title>. <source>Diabetes Care</source><year>2018</year>;<volume>41</volume>:<fpage>e4</fpage>–<lpage>e5</lpage><pub-id pub-id-type="pmid">29133344</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnsson</surname><given-names>KM</given-names></string-name>, <string-name><surname>Ptaszynska</surname><given-names>A</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>B</given-names></string-name>, <string-name><surname>Sugg</surname><given-names>J</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>SJ</given-names></string-name>, <string-name><surname>List</surname><given-names>JF</given-names></string-name></person-group>. <article-title>Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin</article-title>. <source>J Diabetes Complications</source><year>2013</year>;<volume>27</volume>:<fpage>479</fpage>–<lpage>484</lpage><pub-id pub-id-type="pmid">23806570</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosiak</surname><given-names>M</given-names></string-name>, <string-name><surname>Grzeszczak</surname><given-names>S</given-names></string-name>, <string-name><surname>Kosior</surname><given-names>DA</given-names></string-name>, <string-name><surname>Postuła</surname><given-names>M</given-names></string-name></person-group>. <article-title>Emerging treatments in type 2 diabetes: focus on canagliflozin</article-title>. <source>Ther Clin Risk Manag</source><year>2014</year>;<volume>10</volume>:<fpage>683</fpage>–<lpage>689</lpage><pub-id pub-id-type="pmid">25187722</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schernthaner</surname><given-names>G</given-names></string-name>, <string-name><surname>Drexel</surname><given-names>H</given-names></string-name>, <string-name><surname>Moshkovich</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class</article-title>. <source>BMC Endocr Disord</source><year>2019</year>;<volume>19</volume>:<fpage>64</fpage><pub-id pub-id-type="pmid">31208401</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Macha</surname><given-names>S</given-names></string-name>, <string-name><surname>Mattheus</surname><given-names>M</given-names></string-name>, <string-name><surname>Halabi</surname><given-names>A</given-names></string-name>, <string-name><surname>Pinnetti</surname><given-names>S</given-names></string-name>, <string-name><surname>Woerle</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Broedl</surname><given-names>UC</given-names></string-name></person-group>. <article-title>Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment</article-title>. <source>Diabetes Obes Metab</source><year>2014</year>;<volume>16</volume>:<fpage>215</fpage>–<lpage>222</lpage><pub-id pub-id-type="pmid">23859488</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geerlings</surname><given-names>S</given-names></string-name>, <string-name><surname>Fonseca</surname><given-names>V</given-names></string-name>, <string-name><surname>Castro-Diaz</surname><given-names>D</given-names></string-name>, <string-name><surname>List</surname><given-names>J</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>S</given-names></string-name></person-group>. <article-title>Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria</article-title>. <source>Diabetes Res Clin Pract</source><year>2014</year>;<volume>103</volume>:<fpage>373</fpage>–<lpage>381</lpage><pub-id pub-id-type="pmid">24529566</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neuen</surname><given-names>BL</given-names></string-name>, <string-name><surname>Young</surname><given-names>T</given-names></string-name>, <string-name><surname>Heerspink</surname><given-names>HJL</given-names></string-name>, <etal/></person-group>. <article-title>SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2019</year>;<volume>7</volume>:<fpage>845</fpage>–<lpage>854</lpage><pub-id pub-id-type="pmid">31495651</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Jardine</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <etal/>.; <collab>CREDENCE Trial Investigators</collab></person-group>. <article-title>Canagliflozin and renal outcomes in type 2 diabetes and nephropathy</article-title>. <source>N Engl J Med</source><year>2019</year>;<volume>380</volume>:<fpage>2295</fpage>–<lpage>2306</lpage><pub-id pub-id-type="pmid">30990260</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heerspink</surname><given-names>HJL</given-names></string-name>, <string-name><surname>Stefánsson</surname><given-names>BV</given-names></string-name>, <string-name><surname>Correa-Rotter</surname><given-names>R</given-names></string-name>, <etal/>.; <collab>DAPA-CKD Trial Committees and Investigators</collab></person-group>. <article-title>Dapagliflozin in patients with chronic kidney disease</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>1436</fpage>–<lpage>1446</lpage><pub-id pub-id-type="pmid">32970396</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>11. Microvascular complications and foot care: <italic toggle="yes">Standards of Medical Care in Diabetes–2021</italic></article-title>. <source>Diabetes Care</source><year>2021</year>;<volume>44</volume>(<issue>Suppl. 1</issue>):<fpage>S151</fpage>–<lpage>S167</lpage><pub-id pub-id-type="pmid">33298422</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group</collab></person-group>. <article-title>KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease</article-title>. <source>Kidney Int Suppl</source><year>2020</year>;<volume>98</volume>:<fpage>S1</fpage>–<lpage>S115</lpage></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Raz</surname><given-names>I</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>MP</given-names></string-name>, <etal/>.; <collab>DECLARE–TIMI 58 Investigators</collab></person-group>. <article-title>Dapagliflozin and cardiovascular outcomes in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2019</year>;<volume>380</volume>:<fpage>347</fpage>–<lpage>357</lpage><pub-id pub-id-type="pmid">30415602</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yavin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Mansfield</surname><given-names>TA</given-names></string-name>, <string-name><surname>Ptaszynska</surname><given-names>A</given-names></string-name>, <string-name><surname>Johnsson</surname><given-names>K</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>S</given-names></string-name>, <string-name><surname>Johnsson</surname><given-names>E</given-names></string-name></person-group>. <article-title>Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis</article-title>. <source>Diabetes Ther</source><year>2016</year>;<volume>7</volume>:<fpage>125</fpage>–<lpage>137</lpage><pub-id pub-id-type="pmid">26758563</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oshima</surname><given-names>M</given-names></string-name>, <string-name><surname>Jardine</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice</article-title>. <source>Kidney Int</source><year>2021</year>;<volume>99</volume>:<fpage>999</fpage>–<lpage>1009</lpage><pub-id pub-id-type="pmid">33316282</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weir</surname><given-names>MR</given-names></string-name>, <string-name><surname>Slee</surname><given-names>A</given-names></string-name>, <string-name><surname>Sun</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program</article-title>. <source>Clin Kidney J</source><year>2020</year>;<volume>14</volume>:<fpage>1396</fpage>–<lpage>1402</lpage><pub-id pub-id-type="pmid">34221371</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agarwal</surname><given-names>R</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>A</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <etal/>.; <collab>FIDELIO-DKD Investigators</collab></person-group>. <article-title>Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial</article-title>. <source>J Am Soc Nephrol</source><year>2022</year>;<volume>33</volume>:<fpage>225</fpage>–<lpage>237</lpage><pub-id pub-id-type="pmid">34732509</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>R</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <etal/>.; <collab>FIDELIO-DKD Investigators</collab></person-group>. <article-title>Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>2219</fpage>–<lpage>2229</lpage><pub-id pub-id-type="pmid">33264825</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <etal/>.; <collab>CANVAS Program Collaborative Group</collab></person-group>. <article-title>Canagliflozin and cardiovascular and renal events in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>644</fpage>–<lpage>657</lpage><pub-id pub-id-type="pmid">28605608</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jardine</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <etal/>.; <collab>CREDENCE Study Investigators</collab></person-group>. <article-title>Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial</article-title>. <source>J Am Soc Nephrol</source><year>2020</year>;<volume>31</volume>:<fpage>1128</fpage>–<lpage>1139</lpage><pub-id pub-id-type="pmid">32354987</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
